Impact of arterial access site on outcomes after primary percutaneous coronary intervention: Prespecified subgroup analysis from the EUROMAX trial

Circulation: Cardiovascular Interventions

Volumn 8, Issue 6, 2015, Pages

  Hamon, Martial ^a   Coste, Pierre ^b   Van'T Hof, Arnoud ^c   Ten Berg, Jurrien ^d   Clemmensen, Peter ^e   Tabone, Xavier ^f   Benamer, Hakim ^g   Kristensen, Steen D ^h   Cavallini, Claudio ⁱ   Marzocchi, Antonio ^j   Hamm, Christian ^k   Kanic, Vojko ^l   Bernstein, Debra ^m   Anthopoulos, Prodromos ^m   Deliargyris, Efthymios N ^m   Steg, Philippe Gabriel ^n,o,p  

^a UNIVERSITÉ DE CAEN   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c ISALA HOSPITAL   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Service de cardiologie   (France)

^g Hopital Europeen La Roseraie   (France)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

^j UNIVERSITY OF BOLOGNA   (Italy)

^k KERCKHOFF HEART CENTER   (Germany)

^l UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^m MEDICINES COMPANY   (United States)

ⁿ UNIVERSITÉ PARIS DESCARTES   (France)

^o French Alliance for Cardiovascular Trials   (France)

^p ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

Bivalirudin; hemorrhage; myocardial infarction; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICAGRELOR; ANTITHROMBIN; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ARTERIAL ACCESS; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEATH; FEMALE; FEMORAL ARTERY; HEART INFARCTION; HEART REINFARCTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VASCULAR ACCESS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; MIDDLE AGED; PROCEDURES; SURGERY;

AGED; ANTITHROMBINS; FEMALE; FEMORAL ARTERY; HEMORRHAGE; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RADIAL ARTERY; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84937611080     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.114.002049     Document Type: Article

References (20)

1. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863.
2. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-2216. doi: 10.1056/NEJMoa062437.
3. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230. doi: 10.1056/NEJMoa0708191.
4. Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet. 2014;384:599-606. doi: 10.1016/S0140-6736(14)61216-2.
5. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569-2619. doi: 10.1093/eurheartj/ehs215.
6. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso JE, Tracy CM, Woo YJ, Zhao DX; CF/AHA Task Force. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529-555. doi: 10.1161/CIR.0b013e3182742c84.
7. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193-2204. doi: 10.1016/S0140-6736(11)60764-2.
8. Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Ten Berg J, Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Campo dell' Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P; EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;369:2207-2217. doi: 10.1056/NEJMoa1311096.
9. Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH; HEAT-PPCI Trial Investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEATPPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014;384:1849-1858. doi: 10.1016/S0140-6736(14)60924-7.
10. Zeymer U, van 't Hof A, Adgey J, Nibbe L, Clemmensen P, Cavallini C, ten Berg J, Coste P, Huber K, Deliargyris EN, Day J, Bernstein D, Goldstein P, Hamm C, Steg PG. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. Eur Heart J. 2014;35:2460-2467. doi: 10.1093/eurheartj/ehu214.
11. Steg PG, van 't Hof A, Clemmensen P, Lapostolle F, Dudek D, Hamon M, Cavallini C, Gordini G, Huber K, Coste P, Thicoipe M, Nibbe L, Steinmetz J, Ten Berg J, Eggink GJ, Zeymer U, Campo dell' Orto M, Kanic V, Deliargyris EN, Day J, Schuette D, Hamm CW, Goldstein P. Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized openlabel ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary intervention. Am Heart J. 2013;166:960-967.e6. doi: 10.1016/j.ahj.2013.08.025.
12. Hamon M, Lipiecki J, Carrié D, Burzotta F, Durel N, Coutance G, Boudou N, Colosimo C, Trani C, Dumonteil N, Morello R, Viader F, Claise B, Hamon M. Silent cerebral infarcts after cardiac catheterization: a randomized comparison of radial and femoral approaches. Am Heart J. 2012;164:449-454.e1. doi: 10.1016/j.ahj.2012.04.005.
13. Ratib K, Mamas MA, Routledge HC, Ludman PF, Fraser D, Nolan J. Influence of access site choice on incidence of neurologic complications after percutaneous coronary intervention. Am Heart J. 2013;165:317-324. doi: 10.1016/j.ahj.2012.10.015.
14. Jolly SS, Yusuf S, Cairns J, Niemelä K, Xavier D, Widimsky P, Budaj A, Niemelä M, Valentin V, Lewis BS, Avezum A, Steg PG, Rao SV, Gao Afzal R, Joyner CD, Chrolavicius S, Mehta SR; RIVAL trial group. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet. 2011;377:1409-1420. doi: 10.1016/S0140-6736(11)60404-2.
15. Hamon M, Pristipino C, Di Mario C, Nolan J, Ludwig J, Tubaro M, Sabate M, Mauri-Ferré J, Huber K, Niemelä K, Haude M, Wijns W, Dudek D, Fajadet J, Kiemeneij F; European Association of Percutaneous Cardiovascular Interventions; Working Group on Acute Cardiac Care of the European Society of Cardiology; Working Group on Thrombosis on the European Society of Cardiology. Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care and Thrombosis of the European Society of Cardiology. EuroIntervention. 2013;8:1242-1251. doi: 10.4244/EIJV8I11A192.
16. Nicolau JC, Moreira HG, Baracioli LM, Serrano CV Jr, Lima FG, Franken M, Giraldez RR, Ganem F, Kalil Filho R, Ramires JA, Mehran R. The bleeding risk score as a mortality predictor in patients with acute coronary syndrome. Arq Bras Cardiol. 2013;101:511-518. doi: 10.5935/abc.20130223.
17. Ariza-Solé A, Sánchez-Elvira G, Sánchez-Salado JC, Lorente-Tordera V, Salazar-Mendiguchiá J, Sánchez-Prieto R, Romaguera-Torres R, Ferreiro-Gutiérrez JL, Gómez-Hospital JA, Cequier-Fillat A. CRUSADE bleeding risk score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Thromb Res. 2013;132:652-658. doi: 10.1016/j.thromres.2013.09.019.
18. Romagnoli E, Biondi-Zoccai G, Sciahbasi A, Politi L, Rigattieri S, Pendenza G, Summaria F, Patrizi R, Borghi A, Di Russo C, Moretti C, Agostoni P, Loschiavo P, Lioy E, Sheiban I, Sangiorgi G. Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am Coll Cardiol. 2012;60:2481-2489. doi: 10.1016/j.jacc.2012.06.017.
19. Baklanov DV, Kim S, Marso SP, Subherwal S, Rao SV. Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: analysis from the national cardiovascular data registry. Circ Cardiovasc Interv. 2013;6:347-353. doi: 10.1161/CIRCINTERVENTIONS.113.000279.
20. Valgimigli M, Calabrò P, Cortese B, Frigoli E, Garducci S, Rubartelli P, Andò G, Santarelli A, Galli M, Garbo R, Repetto A, Ierna S, Briguori C, Limbruno U, Violini R, Gagnor A; MATRIX Investigators. Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial. J Cardiovasc Transl Res. 2014;7:101-111. doi: 10.1007/s12265-013-9537-1.